{'fraction_non_alphanumeric': 0.048343777976723366, 'fraction_numerical': 0.03491495076096687, 'mean_word_length': 4.5073891625615765, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 1, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The pharmacodynamic effects of rocuronium during general anesthesia in patients with type 2 diabetes mellitus.

AIM
The aim of this prospective study was to investigate whether the neuromuscular response to rocuronium is affected by the presence of type 2 diabetes mellitus.


METHODS
Neuromuscular functions were measured after the administration of 0.6 mg/kg rocuronium with train-of-four stimulations in patients with type 2 diabetes mellitus (DM, N=14) and without diabetes mellitus (control, N=14) during isoflurane based general anesthesia. The onset time, clinical duration and recovery index of rocuronium were compared in the two groups.


RESULTS
The mean onset time (136 +/- 40 vs 118 +/- 20 s), clinical duration (51 +/- 11 vs 48 +/- 11 min) and recovery index (6.0 +/- 2.5 vs 5.9 +/- 1.4 min) of the neuromuscular block were not significantly different between the DM and control groups, respectively (p>0.05).


CONCLUSIONS
The present study has proven that the rocuronium-induced neuromuscular block was not affected in patients with type 2 diabetes mellitus during isoflurane based general anesthesia.